Caring Brands Eyes Nasdaq Listing, $4M Public Offering for Wellness Products

TL;DR

**CABR's Nasdaq aspirations and $4M offering are a high-stakes bet on Photocil's relaunch, but the prior U.S. market failure makes this a speculative play.**

AI Summary

Caring Brands, Inc. (CABR) is a wellness consumer products company preparing for a public offering of 1,000,000 shares of common stock at an assumed price of $4.00 per share, aiming to raise $4,000,000 in gross proceeds. After underwriting discounts of $320,000 (8%) and a non-accountable expense allowance of $40,000 (1%), the company expects net proceeds of $3,680,000 before other expenses. CABR is seeking to list its common stock on The Nasdaq Capital Market under the symbol 'CABR', moving from its current OTCQB listing under 'CBRA', where its last reported sale price was $4.50 on September 5, 2025. A key product, Photocil, an OTC cosmetic for vitiligo and psoriasis, was briefly launched in the U.S. from December 2022 to February 2023 but was removed due to insufficient sales, with a relaunch targeted for 2026. The company also plans for the potential resale of 2,610,000 shares by selling stockholders, including 2,110,000 warrant shares from private placements between April and June 2024. The global phototherapy treatment market, relevant to Photocil, is projected to grow from approximately $1.9 billion in 2023 to $3.23 billion by 2033, at a CAGR of 5.2%.

Why It Matters

This S-1/A filing signals Caring Brands' ambition to transition from OTCQB to Nasdaq, a move that could significantly enhance its visibility and liquidity for investors. The public offering of 1,000,000 shares aims to inject $3.68 million in net proceeds, crucial for funding the relaunch of its key product, Photocil, in the competitive U.S. market by 2026. For employees, a successful Nasdaq listing and capital raise could provide greater stability and growth opportunities. Customers might benefit from increased marketing and availability of products like Photocil, especially given the projected 5.2% CAGR in the global phototherapy market, which presents a substantial opportunity for CABR.

Risk Assessment

Risk Level: high — The risk level is high due to the company's prior failure to achieve sufficient sales for Photocil in the U.S. market from December 2022 to February 2023, leading to its removal. Furthermore, the offering is contingent on Nasdaq listing approval, and 'there is no assurance that an active trading market for our common stock will develop or be sustained.' The company also states that 'an investment in our securities is highly speculative, involves a high degree of risk and should be considered only by persons who can afford the loss of their entire investment.'

Analyst Insight

Investors should approach CABR with extreme caution, recognizing the speculative nature of this offering. Await confirmation of the Nasdaq listing and closely scrutinize the company's detailed plans for Photocil's 2026 relaunch, particularly regarding sales and marketing strategies, before considering any investment.

Key Numbers

• $4.00 — Assumed Public Offering Price Per Share (Basis for the $4,000,000 gross proceeds)
• $4,000,000 — Total Gross Proceeds from Public Offering (Expected capital raised before expenses)
• $320,000 — Underwriting Discounts, Expenses and Commissions (Represents 8% of gross proceeds)
• $3,680,000 — Proceeds to Company, Before Expenses (Net capital expected after underwriting fees)
• 1,000,000 — Shares Offered in Public Offering (Number of common stock shares being sold to the public)
• 2,610,000 — Shares for Resale by Selling Stockholders (Includes warrant shares and shares held by a shareholder)
• $4.50 — Last Reported Sale Price on OTCQB (Price per share on September 5, 2025, before Nasdaq listing)
• 5.2% — CAGR of Global Phototherapy Treatment Market (Projected growth rate from 2023 to 2033)
• $1.9 billion — Global Phototherapy Treatment Market Size (2023) (Estimated market value in 2023)
• $3.23 billion — Projected Global Phototherapy Treatment Market Size (2033) (Estimated market value by 2033)

Key Players & Entities

• Caring Brands, Inc. (company) — Registrant and issuer of common stock
• Glynn Wilson (person) — Chief Executive Officer of Caring Brands, Inc.
• D. BORAL CAPITAL (company) — Sole Underwriter for the public offering
• Securities and Exchange Commission (regulator) — Regulatory body for the S-1/A filing
• The Nasdaq Capital Market (company) — Targeted stock exchange for CABR's listing
• OTCQB (company) — Current trading market for CABR's common stock
• Future Market Insights (company) — Source of market data for phototherapy treatment market
• Gregory Sichenzia, Esq. (person) — Counsel for the company from Sichenzia Ross Ference Carmel LLP
• Arthur S. Marcus, Esq. (person) — Counsel for the company from Sichenzia Ross Ference Carmel LLP
• Joseph M. Lucosky, Esq. (person) — Counsel for the company from Lucosky Brookman LLP

FAQ

Risk Factors

• Reliance on Photocil Product Performance [high — operational]: The company's success is heavily dependent on the performance of its key product, Photocil. The product was previously removed from the U.S. market due to insufficient sales, indicating potential market acceptance issues. A successful relaunch in 2026 is critical, but there's no guarantee of improved sales.
• Limited Operating History and Profitability Concerns [high — financial]: Caring Brands has a limited operating history, particularly with its core product, Photocil. The company's ability to generate sustainable revenue and achieve profitability is unproven, raising concerns about its long-term financial viability.
• Regulatory Compliance for OTC Products [medium — regulatory]: As a seller of Over-The-Counter (OTC) cosmetic and health products, Caring Brands must comply with regulations from bodies like the FDA. Changes in regulations or failure to maintain compliance could impact product sales and market access.
• Competition in the Wellness and Phototherapy Market [medium — market]: The global phototherapy treatment market is projected to grow, but it is also competitive. Caring Brands faces competition from established players and new entrants, which could affect market share and pricing power.
• Dependence on Public Offering Proceeds [high — financial]: The company is seeking to raise $4,000,000 in gross proceeds from this public offering. A significant portion of its future operations and growth plans are contingent on the successful completion of this offering at the assumed price of $4.00 per share.
• Potential Resale of Shares by Selling Stockholders [medium — operational]: The potential resale of 2,610,000 shares by selling stockholders, including warrant shares, could create downward pressure on the stock price if these shares are sold in large volumes shortly after the offering.

Industry Context

Caring Brands operates within the wellness consumer products sector, with a specific focus on phototherapy treatments. The global phototherapy market is experiencing growth, projected to reach $3.23 billion by 2033 from $1.9 billion in 2023, driven by increasing awareness and demand for non-invasive treatment options. However, this market is competitive, requiring companies to navigate regulatory landscapes and demonstrate product efficacy to gain market share.

Regulatory Implications

As a seller of OTC cosmetic and health products, Caring Brands is subject to regulations by health authorities such as the FDA. Compliance with labeling, manufacturing, and marketing standards is crucial. Any shifts in regulatory requirements or enforcement actions could significantly impact product availability and sales.

What Investors Should Do

1. Evaluate the viability of Photocil's relaunch strategy.
2. Assess the dilution risk from selling stockholders.
3. Monitor the company's ability to achieve profitability.
4. Consider the competitive landscape.

Key Dates

• 2022-12-01: Initial U.S. launch of Photocil — Marked the company's entry into the U.S. market with its key product.
• 2023-02-01: Photocil removed from U.S. market — Indicated initial challenges with sales and market acceptance, leading to a strategic pause.
• 2024-04-01: Start of private placement warrant issuance — Led to the creation of warrant shares that are part of the resale offering.
• 2025-09-05: Last reported sale price on OTCQB — Established a benchmark price of $4.50 per share prior to the Nasdaq listing.
• 2026-01-01: Targeted Photocil relaunch — Represents a key future event for the company's revenue generation strategy.

Glossary

S-1/A

An amendment to a registration statement filed with the SEC for a public offering of securities. It provides detailed information about the company, its business, financials, and the offering itself. (This document is the primary source of information for investors considering the Caring Brands IPO.)

OTC

Over-The-Counter. Refers to securities trading outside of a formal exchange like Nasdaq or NYSE, often with less stringent reporting requirements. (CABR is moving from the OTCQB market to Nasdaq, indicating a step up in its public market status.)

Phototherapy

A type of medical treatment that uses specific wavelengths of light to treat certain skin conditions. (This is the market segment relevant to Caring Brands' product, Photocil.)

CAGR

Compound Annual Growth Rate. A measure of the average annual growth rate of an investment over a specified period of time longer than one year. (Used to project the future growth of the phototherapy market, indicating market opportunity.)

Underwriting Discounts

Fees paid by the issuer to the investment banks (underwriters) for their services in selling the securities to the public. (These fees reduce the net proceeds the company receives from the IPO.)

Warrant Shares

Shares of common stock that can be purchased at a specified price by the holder of a warrant. These are often issued in private placements. (A significant portion of the shares available for resale are warrant shares, which could impact market supply.)

Year-Over-Year Comparison

This S-1/A filing represents Caring Brands' initial step towards a public offering on Nasdaq, a significant transition from its OTCQB listing. Key metrics such as revenue, profitability, and margins are not yet available for comparison as this is a pre-IPO filing. New risks related to the public offering process, including underwriting fees and potential share dilution from selling stockholders, are now prominent.

Key Financial Figures

• $0.001 — 0,000 shares of common stock, par value $0.001 (the “Common Stock”) throug
• $4.50 — ce of our common stock on the OTCQB was $4.50 per share. The final public offering pr
• $4.00 — fering price per share is assumed to be $4.00 per share. The table above assumes no e
• $0.32 — proceeds of the offering per share (or $0.32 per share). We have agreed to pay a non
• $0.04 — of the gross proceeds of this offering ($0.04 per share) payable to the representativ
• $1.9billion — market is projected to rise from ~ USD $1.9billion in 2023 to ~ USD $3.23billion by 2033,
• $3.23billion — from ~ USD $1.9billion in 2023 to ~ USD $3.23billion by 2033, at a CAGR of around 5.2% durin
• $34 billion — psoriasis treatment market was worth ~ $34 billion globally in the 12 months ending June 2
• $54 — lobal market is expected to reach ~ USD $54-67 billion by 2030. Estimates from a re

Filing Documents

• forms-1a.htm (S-1/A) — 2174KB
• ex4-3.htm (EX-4.3) — 71KB
• ex10-14.htm (EX-10.14) — 20KB
• ex10-15.htm (EX-10.15) — 133KB
• ex10-16.htm (EX-10.16) — 53KB
• ex10-17.htm (EX-10.17) — 64KB
• ex10-18.htm (EX-10.18) — 107KB
• ex10-19.htm (EX-10.19) — 79KB
• ex10-20.htm (EX-10.20) — 58KB
• ex10-21.htm (EX-10.21) — 57KB
• ex10-22.htm (EX-10.22) — 106KB
• ex23-1.htm (EX-23.1) — 5KB
• formdrs_001.jpg (GRAPHIC) — 1KB
• audit_001.jpg (GRAPHIC) — 32KB
• fin_001.jpg (GRAPHIC) — 1KB
• fin_002.jpg (GRAPHIC) — 1KB
• fin_003.jpg (GRAPHIC) — 1KB
• ex10-16_001.jpg (GRAPHIC) — 6KB
• ex23-1_001.jpg (GRAPHIC) — 11KB
• ex10-19_001.jpg (GRAPHIC) — 3KB
• ex10-19_002.jpg (GRAPHIC) — 3KB
• ex4-3_002.jpg (GRAPHIC) — 1KB
• 0001641172-25-026870.txt ( ) — 3013KB

USE OF PROCEEDS

USE OF PROCEEDS 26 DIVIDEND POLICY 26 Consolidated Financial Statements 28 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 31

BUSINESS

BUSINESS 36 MANAGEMENT 47 EXECUTIVE AND DIRECTOR COMPENSATION 52 CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS 53

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 57

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 58 SHARES ELIGIBLE FOR FUTURE SALE 61 CERTAIN INCOME TAX CONSIDERATIONS 63

UNDERWRITING

UNDERWRITING 66 LEGAL MATTERS 71 EXPERTS 71 WHERE YOU CAN FIND MORE INFORMATION 71 INDEX TO FINANCIAL STATEMENTS F-1 Please read this prospectus carefully. It describes our business, our financial condition, and our results of operations. We have prepared this prospectus so that you will have the information necessary to make an informed investment decision. You should rely only on the information contained in this prospectus or in any related free writing prospectus. We have not, and the underwriters have not, authorized anyone to provide you with information different from that contained in this prospectus or in any related free writing prospectus. Neither we, the selling stockholders nor any of the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectuses we have prepared. Neither we, the selling stockholders nor any of the underwriters take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus is current only as of its date, regardless of the time of delivery of this prospectus or of any sale of our common stock. For investors outside the United States: Neither we, the selling stockholders nor any of the underwriters have done anything that would permit this offering or the possession or distribution of this prospectus in any jurisdiction where action for those purposes is required, other than in the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside of the United

View Full Filing

View this S-1/A filing on SEC EDGAR